I still don’t see the need to do a second P3 trial, with recruitment for CUV107 expected to be completed at the end of 2026, results will take another 6-12 months (based on CUV105) to arrive putting us around mid to late 2027. Then submission to the FDA… if the results from CUV105 support approval they should go with those, and use the second study to examine Scenesse in a wider range of skin types for a potential indication expansion down the track.
Ann: SCENESSE in Vitiligo - A Global Update, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$9.83 |
Change
-0.350(3.44%) |
Mkt cap ! $492.7M | |||
| Open | High | Low | Value | Volume |
| $10.18 | $10.18 | $9.75 | $1.391M | 140.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9965 | $9.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.89 | 370 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CUV (ASX) Chart |